NKTR

Nektar Therapeutics

• TipRanks·20h ago

  Citi opens ‘upside 30-day catalyst watch’ on Nektar into data

• TipRanks·22h ago

  Nektar Therapeutics (NKTR) Receives a Buy from Citi

• TipRanks·22h ago

  Nektar Therapeutics: Buy Rating on Favorable Alopecia Areata Rezpeg Data Outlook and 30‑Day Catalyst Upside Potential

• NASDAQ·22h ago

  Nektar Goes Silent: What's Behind The Quiet Period?

• PR Newswire·1d ago

  NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

• TipRanks·2d ago

  Wall Street Analysts Are Bullish on Top Healthcare Picks

• TipRanks·4d ago

  Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Stock Decline

• PR Newswire·5d ago

  Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR

• TipRanks·03/30 09:20

  Analysts’ Top Healthcare Picks: Insmed (INSM), Nektar Therapeutics (NKTR)

• Benzinga·03/30 07:14

  Reported Saturday, Nektar's Rezpegaldesleukin Shows Statistically Significant EASI Improvements In 393-Patient Phase 2b REZOLVE-AD Trial And Proof-Of-Concept In Alopecia Areata At AAD 2026

• TipRanks·03/29 15:40

  Nektar announces data from Phase 2b Rezolve-AD, Rezolve-AA studies

• Reuters·03/28 16:36

  Nektar plans Phase 3 ZENITH-AD program after rezpegaldesleukin Phase 2b results

• TipRanks·03/26 16:15

  NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Allegedly Concealed Trial Protocol Violations: Levi & Korsinsky

• PR Newswire·03/25 21:10

  Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

• Seeking Alpha·03/25 16:31

  Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B